Back to Journals » OncoTargets and Therapy » Volume 10

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts

Authors Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghea M, Tomuleasa C

Received 21 July 2017

Accepted for publication 13 September 2017

Published 19 October 2017 Volume 2017:10 Pages 5047—5051

DOI https://doi.org/10.2147/OTT.S146973

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Dr Carlos E Vigil


Delia Dima,1,* Liana Oprita,2,* Ana-Maria Rosu,3,* Adrian Trifa,4 Cristina Selicean,1 Vlad Moisoiu,3 Ioana Frinc,1 Mihnea Zdrenghea,1,5 Ciprian Tomuleasa1,3,5

1Department of Hematology, Ion Chiricuta Oncology Institute, 2Department of Dentistry, 3Research Center for Functional Genomics and Translational Medicine, 4Department of Genetics, 5Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

*These authors contributed equally to this work

Abstract: Acute megakaryocytic leukemia (M7-AML) is a rare form of acute myeloid leukemia (AML), which is associated with poor prognosis. The case presented in the current report is a statement for the difficult diagnosis and clinical management of M7-AML in the context of a previous hematologic disorder of undetermined significance and associated genetic abnormalities. Probably, following the complete hematologic remission and further with induction chemotherapy plus tyrosine kinase inhibitor therapy, the clinical management of this case will be followed by a allogeneic bone marrow transplantation, the only proven therapy to improve overall survival.

Keywords: acute megakaryocytic leukemia, BCR–ABL transcript
 

Introduction

Acute megakaryocytic leukemia (M7-AML) is a rare form of acute myeloid leukemia (AML), which is associated with poor prognosis. It is characterized by a proliferation of ≥20% megakaryoblasts identified by specific antigens using flow cytometry with associated extensive myelofibrosis of the bone marrow. The disease is a common form of childhood AML, especially in children with Down syndrome where a better prognosis is observed. In adult AML, it accounts for only 1% of the cases. Although it was first described by von Boros and Korenyi in 1931 and was introduced in the French–American–British (FAB) classification in 1985, due to its low incidence, the clinical experience with this type of AML is limited.13 The few published reports identified some particular features associated with M7-AML such as frequent chromosomal abnormalities, especially of chromosome 3, frequent previous hematologic disorders or myelodysplastic syndromes with poor prognosis.4,5

Immunophenotyping usually reveals positivity for CD33, CD13, CD41, CD61 and factor VIII and negativity for myeloperoxidase (MPO). The reported complete remission rate is ~50%, but the overall survival is 4–10 months. Interestingly, some cases present with BCR–ABL transcript. As M7-AML was found to be an independent negative prognostic factor for survival, some authors suggest that allogeneic stem cell transplantation should be performed in the first remission.6

Herein, we describe the clinical case of a 47-year-old male who was diagnosed in our clinic with M7-AML, which was associated with antecedent hematologic disorder of undetermined significance and two BCR–ABL transcripts.

Case report

A 47-year-old gentleman presented at our clinic in September 2016 for asthenia, which lasted for the previous 4 weeks. The patient’s medical history was consistent with intermittent low-grade fever associated with bicytopenia (neutropenia and thrombocytopenia) for the last 3 years. The patient had no other comorbidities. A bone marrow aspirate was performed in 2013, which showed decreased myeloid series with 35% of granulocytic series and no other abnormalities. The virusologic (hepatitis B, C and HIV viruses) status was negative. The immunological assays were negative. There was no treatment given, and the patient was periodically seen every 3 months. The clinical examination showed a light pale, enlarged lymph nodes; splenomegaly at 6 cm under the costal rib and oral candidiasis. The hematologic examination revealed important leukocytosis at 120×103/μL with 80% blasts (Figure 1), moderate anemia (9 g/dL Hb) and moderate thrombocytopenia (45×103/μL) as well as schistocytes. Biochemical analyses showed increased LDH at 1,895 UI/L (normal range: 230–460 UI/L). Coagulation assays were normal.

Figure 1 Cytology aspect of the M7-AML.
Notes: (AC) Acute megakaryoblastic leukemia showing dysplastic megakaryoblasts. (D and E) Micromegakaryocytes. (F) MPO staining. Magnification ×20.
Abbreviations: MPO, myeloperoxidase; M7-AML, acute megakaryocytic leukemia.

The first bone marrow aspirate was a dry tap. The second bone marrow aspirate was performed, which showed an 30% infiltrate of immature cells with megakaryocytic appearance, signs of dysplasia (micromegakaryocytes) and reduced myeloid series. The bone marrow biopsy revealed 90% infiltration of tumoral monomorphic cells with round nuclei with nucleoli and increased nucleus/cytoplasma ratio. Immunohistochemical staining showed malignant cells that were positive for CD34, CD117, CD61 and Ki-67. The cells were negative for MPO and glycophorin A. Mutational analysis revealed two BCR–ABL transcripts: p210 and p190, transcripts detected by quantitative polymerase chain reaction (qPCR). FLT3 ITD and NPM mutations were negative. HLA phenotype is pending for both the patient and his sister.

Immediately, induction chemotherapy was started consistent with idarubicin at 10 mg/m2/day for days 1, 3 and 5 and continuous infusion of cytarabine at 200 mg/m2/day for 7 days according to standard-of-care protocols.7 Initial induction chemotherapy regimen was supplemented with 150 mg of dasatinib, as reported by Corm et al,8 but without inducing remission. Dasatinib administration was maintained until reinduction chemotherapy was administered using fludarabine, cytarabine and idarubicin (FLAG-Ida protocol)9,10 plus dasatinib. A local antifungal treatment was associated for oral candidiasis. At day 5 of chemotherapy, there was no palpable spleen or enlarged lymph nodes, while bone marrow aplasia appeared. After reinduction chemotherapy, remission was achieved, and the patient is currently waiting for a compatible donor for an allogeneic stem cell transplantation.11

Ethical information

Written informed consent for publication has been obtained from the patient, after all the details of presenting the case in international medical literature were presented and explained.

Discussion

M7-AML is a rare subtype of AML that accounts for ~1% of cases of adult leukemia compared to 3%–10% of childhood leukemia. A bimodal age distribution was reported in the infancy and in the elderly. The clinical features are similar with other types of AML, but organomegaly is noted variably. Cytopenias are a common feature, but up to 30% of patients can present with cytosis. The diagnosis is based on ≥20% blasts with expression of at least one platelet antigen (CD41, CD42b, CD61 or factor V111-related antigen). More than two-third of patients present with myelofibrosis as the bone marrow aspirate may prove difficult. M7-AML may develop as de novo leukemia or secondary to antecedent hematologic disorders such as myelodysplastic or myeloproliferative syndromes. Cytogenetic abnormalities are more frequently observed than other AML subtypes, but they are not specific. The prognosis is poor due to cytogenetic abnormalities, but the authors suggest that M7-AML is an independent poor prognostic factor for survival.1,12,13

The clinical trials for BCR–ABL positive acute lymphoblastic leukemia have proven a poor prognosis for these patients, which is often treated with an allogeneic bone marrow transplantation upfront in the first hematologic remission. There are a few reports of M7-AML with associated BCR–ABL transcript, but there are no published reports for tyrosine kinase inhibitor (ITK) treatment in M7-AML. The few reports published in the literature suggest that patients diagnosed with M7-AML should be considered for allogeneic transplantation due to all the adverse prognostic factors associated with the disease. The complete remission rate is ~50%, comparable with other AML subtypes, but the overall survival is only 4–10 months.1416

Our patient is a middle-aged man with a history of bicytopenia. Retrospectively, the patient could be considered as suffering of cytopenia of undetermined significance. At presentation at our clinic, the patient complained of asthenia. There were enlarged adenopathies and splenomegaly. There was an important leukocytosis with anemia and thrombocytopenia. The first attempt for bone marrow aspirate failed, but the second aspirate revealed an infiltrate of megakaryoblasts that were negative at MPO staining. The immunohistochemistry performed on bone marrow biopsy showed that platelet antigens along with myeloid antigens were present on the leukemic cells. The mutational analysis showed two BCR–ABL transcripts. The patient was treated with induction chemotherapy with good initial response. The HLA phenotype is pending, and the patient will be referred to a transplantation unit as soon as possible.

The case presented in the current report is a statement for the difficult diagnosis and clinical management of M7-AML in the context of a previous hematologic disorder of undetermined significance and associated genetic abnormalities. Probably, following the complete hematologic remission and further with induction chemotherapy plus tyrosine kinase inhibitor therapy, the clinical management of this case will be followed by a allogeneic bone marrow transplantation, the only proven therapy to improve overall survival.

Cytopenias of undetermined significance of the presence of BCR–ABL transcripts have yet to be presented in AML, but in chronic myeloid leukemia (CML), this scenario could be associated with aggressive disease. Abnormal BCR–ABL transcripts might prevent the protein from interacting with small G proteins, as presented by Colla et al17 in AML or blast crisis of CML. By using dasatinib, which has previously been shown to be efficient in the blast crisis of CML,18 that has a clinical evolution similar to that of AML and is accompanied by cytopenias, we present for the first time a case that we consider to have a negative prognosis (BCR–ABL transcripts and cytopenias of unknown significance) and that is treated successfully and creates a bridge toward stem cell transplantation. Such clinical cases may be aggressive at presentation, but using modern combination chemotherapy with small molecule-based therapy and cellular therapies, the patient outcome might be improved. Still, we should emphasize that this manuscript is a case report and should be considered as such with all its limitations. Systematic recordings and long-term follow-ups are required to confirm our results.

Acknowledgment

We deeply acknowledge the contribution of Laura-Ancuta Pop, Bobe Petrushev, Mariana Patiu, Sonia Selicean, Grigore-Aristide Gafencu, Wilhelm-Thomas Micu, Daiana Temian, Ancuta Jurj and Ioana Berindan-Neagoe.

Disclosure

Ana-Maria Rosu received funding from an internal grant of the Iuliu Hatieganu University, awarded to Ph.D. students. Ciprian Tomuleasa received funding from the Romanian Research Ministry, contracts PN-II-RU-TE-2014-4-1783 (awarded to young research teams) and CNFIS-FDI-2017-1350 (awarded to institutional development funds), as well as from an international collaboration grant between Romania and People’s Republic of China, contract 57 BM/2016. The authors report no other conflicts of interest in this work.


References

1.

Giri S, Pathak R, Prouet P, Li B, Martin MG. Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia. Blood. 2014;124(25):3833–3834.

2.

Ishiyama K, Yamaguchi T, Eto T, et al. Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. Leuk Res. 2016;47:47–53.

3.

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.

4.

Von Boros J, Korenyi A. Uber einen fall von akuter megakaryocyblasten-leukamie, zugleich einige bemerkungen zum problem der akuten leukemie. Z Klin Med. 1931;118:679–718.

5.

Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(3):460–462.

6.

Oki Y, Kantarjian HM, Zhou X, et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006;107(3):880–884.

7.

Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79(2):313–319.

8.

Corm S, Renneville A, Rad-Quesnel E, Grardel N, Preudhomme C, Quesnel B. Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia. 2007;21(11):2376–2377.

9.

Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003;82(4):231–235.

10.

Jackson GH. Use of fludarabine in the treatment of acute myeloid leukemia. Hematol J. 2004;5(suppl 1):S62–S67.

11.

Delia M, Pastore D, Carluccio P, et al. FLAG-Ida regimen as bridge therapy to allotransplantation in refractory/relapsed acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 2017;S2152–S2650(17):30285–30289.

12.

Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96(7):2405–2411.

13.

Gassmann W, Löffler H. Acute megakaryoblastic leukemia. Leuk Lymphoma. 1995;18(suppl 1):69–73.

14.

Pagano L, Pulsoni A, Vignetti M, et al; GIMEMA. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia. 2002;16(9):1622–1626.

15.

Duchayne E, Fenneteau O, Pages MP, et al. Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Français d’Hématologie Cellulaire (GFHC). Leuk Lymphoma. 2003;44(1):49–58.

16.

Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.

17.

Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? Haematologica. 2004;89(5):611–613.

18.

Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207–3213.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]